Subgroup analysis showed that compared with non-EGFR-TKI treatment, OS improvement of first-generation EGFR-TKI adjuvant treatment was observed only in stage III NSCLC patients, but not in all stage IB-III patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.